Northern European efforts to boost the use of biosimilar infliximab rather than Janssen's Remicade are gathering pace, with the Norwegian NOR-SWITCH study having been extended by 26 weeks to complete the switch from Remicade to Celltrion's biosimilar, Remsima, and a number of similar studies being conducted by both industry and non-commercial sponsors in the Netherlands.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?